<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002221734
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lyumjev KwikPen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN LISPRO
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        297.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Eli Lilly and Company, Clinton Laboratories" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company, Clinton Laboratories
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV is a man-made fast-acting insulin used to control high blood sugar in adults and children with diabetes mellitus.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.</p><p>&nbsp;</p><p><strong>Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this leaflet. You may need to read it again.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any further questions, ask your doctor, pharmacist or nurse.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.</p><p>&nbsp;</p><p><strong>Do not take </strong><strong>LYUMJEV if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are having an episode of low blood sugar (hypoglycemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an allergy to LYUMJEV or any of the ingredients in LYUMJEV (listed in section 6).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>Before taking LYUMJEV, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney or liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take any other medicines, especially ones called thiazolidinediones (TZDs).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with LYUMJEV.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. Talk with your healthcare provider about the best way to control your blood sugar if you plan to become pregnant or while you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if LYUMJEV passes into your breast milk. You and your healthcare provider should decide if you will take LYUMJEV while you breastfeed.</p><p>&nbsp;</p><p><strong>Tell your healthcare provider about all the medicines you take</strong>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p><strong>Before you start taking LYUMJEV, talk to your healthcare provider about low blood sugar and how to manage it.</strong></p><p><strong>Children and adolescents</strong></p><p>The safety and effectiveness of LYUMJEV in pediatric patients has been established for the age 1 year old.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and LYUMJEV</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Table 1 includes clinically significant drug interactions with LYUMJEV.</p><p>Table 1. Clinically Significant Drug Interactions with LYUMJEV</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Drugs That May Increase the Risk of Hypoglycemia</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Drugs:</strong></p></td><td style="vertical-align:top"><p>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Intervention:</strong></p></td><td style="vertical-align:top"><p>Dose reductions and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Drugs:</strong></p></td><td style="vertical-align:top"><p>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Intervention:</strong></p></td><td style="vertical-align:top"><p>Dose increases and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LYUMJEV</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Drugs:</strong></p></td><td style="vertical-align:top"><p>Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Intervention:</strong></p></td><td style="vertical-align:top"><p>Dose adjustment and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Drugs That May Blunt Signs and Symptoms of Hypoglycemia</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Drugs:</strong></p></td><td style="vertical-align:top"><p>Beta-blockers, clonidine, guanethidine, and reserpine.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Intervention:</strong></p></td><td style="vertical-align:top"><p>Increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>LYUMJEV</strong><strong> with alcohol</strong></p><p><strong>While taking LYUMJEV do not:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drink alcohol or take other medicines that contain alcohol.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p><strong>While taking LYUMJEV do not:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drive or operate heavy machinery, until you know how LYUMJEV affects you.</p><p>&nbsp;</p><p><strong>Do not share your LYUMJEV with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How should I take LYUMJEV?</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Read the <strong>Instructions for Use</strong> that come with your LYUMJEV.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take LYUMJEV exactly as your healthcare provider tells you to. Your healthcare provider will tell you how much LYUMJEV to take and when to take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>LYUMJEV starts acting fast.</strong> Inject LYUMJEV at the beginning of a meal or within 20&nbsp;minutes after you start eating a meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Know the type and strength of insulin you take. <strong>Do not</strong> change the type or amount of insulin you take unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you take different types of insulin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check your insulin label each time you give your injection to make sure you are using the correct insulin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Check your blood sugar levels.</strong> Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar level.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV comes in U-100 (100&nbsp;units/mL) and U-200 (200&nbsp;units/mL) insulin strengths.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV U-200 contains 2&nbsp;times as much insulin (200&nbsp;units/mL) in 1 mL as the standard insulin (100&nbsp;units/mL).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV U-100 and LYUMJEV U-200 can be injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs, or upper arms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV U-100 can also be given in your vein (intravenously) by your healthcare provider. LYUMJEV U-200<strong> cannot</strong> be given in your vein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Change (rotate) your injection sites within the area you choose with each dose</strong> to reduce your risk of getting pits in skin or thickened skin (lipodystrophy) and skin with lumps (localized cutaneous amyloidosis) at the injection sites.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> use the exact same spot for each injection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> inject where the skin has pits, is thickened, or has lumps.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of LYUMJEV, monitor your blood sugar levels to decide if an insulin dose is needed. Continue with your regular dosing schedule at the next meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV comes in a vial, single-patient-use prefilled pen, or in a cartridge. <strong>Do not</strong> use a syringe to remove LYUMJEV from your single-patient-use prefilled pen or cartridge.</p><p><strong>Keep LYUMJEV and all medicines out of the reach of children</strong>.</p><p>&nbsp;</p><p>Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p><strong>Your dose of LYUMJEV may need to change because of:</strong></p><p>a change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or because of other medicines you take.</p><p>&nbsp;</p><p><strong>If you take more LYUMJEV than you should</strong></p><p>Excess insulin administration may cause hypoglycemia and hypokalemia. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.</p><p><em>&nbsp;</em></p><p><strong>If you forget to take LYUMJEV</strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking LYUMJEV</strong></p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>General information about the safe and effective use of LYUMJEV.</strong></p><p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take LYUMJEV for a condition for which it was not prescribed. <strong>Do not </strong>give LYUMJEV to other people, even if they have the same symptoms that you have. It may harm them.</p><p>You can ask your pharmacist or healthcare provider for information about LYUMJEV that is written for health professionals.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>What are the possible side effects of LYUMJEV?</strong></p><p><strong>LYUMJEV may cause serious side effects that can lead to death, including:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>low blood sugar (hypoglycemia). </strong>Signs and symptoms that may indicate low blood sugar include: dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, hunger, anxiety, irritability, or mood changes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>low potassium in your blood (hypokalemia).</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>serious allergic reactions (whole body allergic reaction). Get emergency medical help right away, if you have any of these symptoms of a severe allergic reaction:</strong> &nbsp;a rash over your whole body, trouble breathing, a fast heartbeat, swelling of your face, tongue, or throat, sweating, or feeling faint.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>heart failure.</strong> Taking certain diabetes pills called thiazolidinediones (TZDs) with LYUMJEV may cause heart failure in some people. This can happen even if you have never had heart failure or heart failure problems before. If you already have heart failure it may get worse while you take TZDs with LYUMJEV. Your healthcare provider should monitor you closely while you are taking TZDs with LYUMJEV. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:&nbsp; shortness of breath, swelling of your ankles or feet, or sudden weight gain. Treatment with TZDs and LYUMJEV may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure.</p><p><strong>&nbsp;</strong></p><p><strong>Get emergency medical help if you have</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing, shortness of breath, fast heartbeat, swelling of you face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion.</p><p><strong>The most common side effects of LYUMJEV include:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood sugar (hypoglycemia), reactions at the injection site, allergic reactions, rash, itching (pruritus), thickening or pits at the injection site (lipodystrophy), and weight gain.</p><p><strong>These are not all the possible side effects of LYUMJEV</strong>. Call your doctor for medical advice about side effects. You may report side effects too via the national reporting system.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>This is a Medicament</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow strictly the doctor&#39;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep all medicaments out of reach of children.</p></td></tr></tbody></table><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Refrigerate unopened LYUMJEV vials, pens, and cartridges between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until time of use and keep in the original carton to protect from light. Do not freeze or use LYUMJEV if it has been frozen. Do not expose to direct heat. Discard opened or unopened LYUMJEV vials, pens, and cartridges stored at room temperature below 30&deg;C (86&deg;F) after 28&nbsp;days.</p><p>The storage conditions for vials, pens, and cartridges are summarized in Table 2.</p><p>Table 2. Storage Conditions for Vials, Pens, and Cartridges</p><table border="1" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p><strong>LYUMJEV Presentation</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Not In-use</strong></p><p><strong>(Unopened)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>In-use</strong></p><p><strong>(Opened)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Room Temperature (below 30&deg;C [86&deg;F])</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>Refrigerated</strong></p><p><strong>(2&deg;C to 8&deg;C </strong></p><p><strong>[36&deg;F to 46&deg;F])</strong></p></td><td style="vertical-align:top"><p><strong>Room Temperature (below 30&deg;C [86&deg;F])</strong></p></td><td><p><strong>Refrigerated</strong></p><p><strong>(2&deg;C to 8&deg;C [36&deg;F to 46&deg;F])</strong></p></td></tr><tr><td style="vertical-align:top"><p>10&nbsp;mL vial<sup>a,b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;mL cartridge<sup>b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Do not refrigerate</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;mL LYUMJEV KwikPen (U‑100 and U‑200)<sup>b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Do not refrigerate</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;mL LYUMJEV Junior KwikPen<sup>b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Do not refrigerate</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; In-use (opened) vials, whether or not refrigerated, must be used within 28&nbsp;days.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; When stored at room temperature, LYUMJEV can only be used for a total of 28&nbsp;days including both not in-use (unopened) and in-use (opened) storage time.</p><p>&nbsp;</p><p>Stable up to 14 days when diluted to concentrations of 0.1 to 1 U/mL in 5% Dextrose Injection or 0.9% Sodium Chloride Injection when stored in a refrigerator at 2&deg;C to 8&deg;C [36&deg;F to 46&deg;F] until time of use. The same solutions may be stored for up to 20 hours at room temperature at 20&deg;C to 25&deg;C [(68&deg;F to 77&deg;F)].</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after {abbreviation used for expiry date. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance(s) is insulin lispro</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient(s) are/ glycerol, magnesium chloride hexahydrate, metacresol, sodium citrate dihydrate, treprostinil sodium, zinc oxide (zinc ion), and Water for Injection, USP.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LYUMJEV (insulin lispro) injection is a clear and colorless solution available as shown in Table 3.

Table 3. How Supplied
LYUMJEV	Concentration	Total Units in Presentation	Dose Increment	Package Size
U-100 multiple-dose 10 mL vial	100 units/mL	1,000 units	n/a	1 vial
U-100 single-patient-use 3 mL cartridgea 	100 units/mL	300 units	n/a	5 cartridges
U-100 single-patient-use 3 mL KwikPen	100 units/mL	300 units	1 unit	5 pens
U-100 single-patient-use 3 mL Junior KwikPen	100 units/mL	300 units	0.5 unit	5 pens
U-200 single-patient-use 3 mL KwikPen	200 units/mL	600 units	1 unit	5 pens

a	3 mL cartridge is for use in Eli Lilly and Company's insulin delivery device. Patients need to check their device manual to determine if the LYUMJEV cartridge is compatible for use in other devices.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Eli Lilly and Company, Indianapolis, IN 46285, USA</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line: +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This  leaflet was revised in August 2021
	Version 3

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لومجيف هو عبارة عن إنسولين سريع المفعول من صنع الإنسان، يُستخدم لضبط ارتفاع مستويات السكّر في الدّم لدى البالغين والاطفال&nbsp;المصابين بداء السكّري.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><img width="21" height="18" alt="*" src="file:///C:/Users/L003363/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp;&nbsp;&nbsp; هذا الدواء خاضع لمراقبة إضافية، ما سيتيح تحديثًا سريعًا للمعلومات المتعلّقة بالسلامة. بإمكان المستخدمين المساعدة من خلال الإبلاغ عن أي آثار جانبية قد يعانون منها، وفقًا للتوجيهات المحدّدة في نهاية الفقرة 4.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُرجى قراءة هذه النشرة كاملة بعناية قبل البدء باستخدام هذا الدواء، لِما تحتويه من معلومات مهمّة بالنسبة إلى المستخدم.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بهذه النشرة، إذ إنّك قد تحتاج إلى قراءتها مجددًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أي أسئلة أخرى، يرجى منك توجيهها إلى الطبيب أو الصيدليّ أو الممرّض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا الدواء موصوف لك شخصيًا. لا ينبغي لك إعطاؤه للآخرين لأنّه قد يؤذيهم، حتّى وإن كانت أعراض مرضهم مشابهة للأعراض التي تُعاني منها. &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من أي آثار جانبية، تحدّث مع الطبيب أو الصيدليّ أو الممرّض. ويشمل هذا أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة. راجع الفقرة 4.&nbsp; &nbsp; &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عليك الامتناع عن استخدام لومجيف إذا كنت: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من نوبة انخفاض في مستوى السكر في الدم (نقص سكّر الدّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حساسيّة تجاه لومجيف أو أحد مكوّنات تركيبة لومجيف (المذكورة في الفقرة 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>قبل البدء باستخدام لومجيف، عليك إطلاع مقدّم الرعاية الصحية على أيّ ظروف صحية قد تعاني منها، بما في ذلك:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكليتين أو الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية أخرى، خصوصًا من فئة الثيازوليدينديونات (TZDs).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من قصور في القلب أو من مشاكل قلبية أخرى. إذا كنت تعاني من قصور في القلب، فإنّ حالتك قد تتفاقم إذا استخدمت الثيازوليدينديونات بالتزامن مع لومجيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو تخطّطين للإنجاب. استشيري مقدّم الرعاية الصحية بشأن الطريقة الأفضل لضبط مستوى السكّر في دمك إذا كُنت تخطّطين للإنجاب أو خلال فترة حملك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعة أو تخطّطين للإرضاع. من غير المعروف ما إذا كان لومجيف ينتقل إلى حليب الأم. يتعيّن عليك وعلى مقدّم الرعاية الصحية اتّخاذ القرار بشأن استخدام لومجيف خلال فترة الإرضاع. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عليك إطلاع مقدّم الرعاية الصحية على جميع الأدوية التي تتناولها</strong>، بما فيها الأدوية الموصوفة لك وتلك المتاحة بدون وصفة طبية، والفيتامينات والمكمّلات العشبيّة. &nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>كما عليك أن تتحدّث مع مقدّم الرعاية الصحية عن انخفاض مستوى السكّر في الدمّ وكيفية معالجته، قبل البدء باستخدام لومجيف. &nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">تم تقييم سلامة لومجيف وفعاليّته لدى المرضى من الأطفال من عمر السنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لومجيف وأدوية أخرى</strong></p><p dir="RTL">عليك إطلاع الطبيب أو الصيدلي إذا كنت تستخدم، أو &nbsp;استخدمت في الفترة الأخيرة أو يمكن أن تستخدم أدوية أخرى.</p><p dir="RTL">يضمّ الجدول 1 التفاعلات الدوائية ذات الأهمية السريرية مع لومجيف. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجدول 1. التفاعلات الدوائية ذات الأهمية السريرية مع لومجيف</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الأدوية التي قد تزيد من خطر نقص سكر الدم&nbsp; </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأدوية:</strong></p></td><td style="vertical-align:top"><p dir="RTL">الأدوية المضادة للسكري، مثبطات الإنزيم المحول للأنجيوتنسين، حاصرات مستقبلات الأنجيوتنسين 2، الديسوبيراميد، الفيبرات، الفلوكستين، مثبطات الأكسيداز أحادي الأمين، البنتوكسيفيلين، البراملينتيد، الساليسيلات، نظائر السوماتوستاتين (كالأوكتريوتيد)، ومضادات السلفوناميد الحيوية. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإجراء الموصى به:</strong></p></td><td style="vertical-align:top"><p dir="RTL">قد يتعيّن خفض الجرعة وزيادة وتيرة قياس مستوى السكّر في الدّم في حالة استخدام لومجيف بالتزامن مع هذه الأدوية. &nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الأدوية التي قد تضعف تأثير لومجيف الخافض لمستوى السكّر في الدّم </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأدوية:</strong></p></td><td style="vertical-align:top"><p dir="RTL">مضادات الذهان غير التقليدية (كالأولانزابين والكلوزابين)، الستيرويدات القشرية، الدانازول، مدرّات البول، الإستروجينات، الغلوكاغون، الإِيزونيازيد، النياسين، وسائل منع الحمل الفموية، الفينوثيازينات، البروجيستوجينات (في وسائل منع الحمل الفموية مثلًا)، مثبطات البروتياز، السوماتروبين، المحاكيات الودية (كالألبوتيرول، الإبينفرين، التيربوتالين)، وهرمونات الغدة الدرقية.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإجراء الموصى به:</strong></p></td><td style="vertical-align:top"><p dir="RTL">قد يتعيّن زيادة الجرعة وزيادة وتيرة قياس مستوى السكّر في الدّم في حالة استخدام لومجيف بالتزامن مع هذه الأدوية.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الأدوية التي قد تعزّز أو تُضعف تأثير لومجيف الخافض لمستوى السكّر في الدّم </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأدوية:</strong></p></td><td style="vertical-align:top"><p dir="RTL">الكحول، حاصرات بيتا، الكلونيدين وأملاح الليثيوم. قد يؤدي البنتاميدين إلى نقص سكّر الدّم، الذي قد تتبعه أحيانًا حالة فرط سكّر الدّم. &nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإجراء الموصى به:</strong></p></td><td style="vertical-align:top"><p dir="RTL">قد يتعيّن تعديل الجرعة وزيادة وتيرة قياس مستوى السكّر في الدّم في حالة استخدام لومجيف بالتزامن مع هذه الأدوية.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الأدوية التي قد تخفف من علامات وأعراض نقص سكر الدم&nbsp;&nbsp; </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأدوية: </strong></p></td><td style="vertical-align:top"><p dir="RTL">حاصرات بيتا، الكلونيدين، الغوانيثيدين والريزيربين.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإجراء الموصى به: </strong></p></td><td style="vertical-align:top"><p dir="RTL">قد يتعيّن زيادة وتيرة قياس مستوى السكّر في الدّم في حالة استخدام لومجيف بالتزامن مع هذه الأدوية.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لومجيف مع الكحول </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء استخدام لومجيف، ينبغي الامتناع عن: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الكحول أو أخذ أدوية أخرى تحتوي على الكحول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعة، أو تشكّين بأنّك حامل أو تخطّطين للإنجاب، استشيري الطبيب أو الصيدلي قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة وتشغيل الآلات </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء استخدام لومجيف، ينبغي الامتناع عن: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيادة أو تشغيل الآلات الثقيلة، إلى أن تعرف تأثير لومجيف عليك.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>امتنع عن التشارك في استخدام لومجيف مع أشخاص آخرين، حتّى وإن تمّ تغيير الإبرة، فذلك قد يتسبّب بانتقال عدوى خطيرة منك أو إليك.&nbsp; </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي استخدام هذا الدواء دائمًا بحسب التعليمات الدقيقة للطبيب أو الصيدلي. وإذا لم تكن متأكّدًا، عليك استشارة طبيبك أو الصيدلي. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفيّة أخذ لومجيف</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقرأ <strong>إرشادات الاستخدام</strong> المرفقة مع لومجيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم لومجيف مع الالتزام بدقّة بتعليمات مقدّم الرعاية الصحية. سيحدّد لك مقدّم الرعاية الصحية جرعة لومجيف التي يتعيّن عليك أخذها والوقت المناسب لأخذها.&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لومجيف سريع المفعول، لذا يوصى بأخذ الحقنة في بداية الوجبة أو في غضون 20 دقيقة بعد بدء تناول الوجبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الضروري أن تعرف نوع الإنسولين الذي تستخدمه وتركيزه. و<strong>لا</strong> ينبغي أن تغيّر نوع أو كمية الإنسولين التي تأخذها إلّا بناءً على تعليمات مقدّم الرعاية الصحية. قد يتعيّن تغيير كميّة الإنسولين والوقت الأمثل لأخذها في حال كنت تستخدم أنواعًا مختلفة من الإنسولين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقّق من الملصق على عبوة الإنسولين قبل أخذ الحقنة في كلّ مرة للتأكد من أنّك تستخدم النوع الصحيح من الإنسولين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحقّق من مستويات السكّر في دمك</strong>. اسأل مقدّم الرعاية الصحية حول ما ينبغي أن تكون عليه مستويات السكّر لديك ومتى يتعيّن عليك التحقّق من مستويات السكّر في دمك.&nbsp;&nbsp; &nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنسولين لومجيف متوفّر بتركيز U-100 (100 وحدة/مل) وU-200 (200 وحدة/مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي لومجيفU-200 &nbsp;على ضعفي كمية الإنسولين (200 وحدة/مل) في كلّ مليلتر، مقارنة بالإنسولين العادي (100 وحدة/مل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن حقن لومجيف U-100 ولومجيف U-200 تحت الجلد في منطقة المعدة، أو الردفين، أو أعلى الساقَين، أو أعلى الذراعَين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يُمكن لمقدّم الرعاية الصحية أن يعطيك لومجيف &nbsp;U-100عن طريق الوريد. أمّا لومجيف U-200 <strong>فلا</strong> يُمكن أخذه عن طريق الوريد.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غيّر موضع الحقن (بالتناوب)، في كلّ مرة، ضمن المنطقة التي تختارها</strong>، لتقليل خطر الإصابة بحفر في الجلد أو ازدياد سماكته (الحثل الشحمي) و ظهور كتل في الجلد (الداء النشواني الجلدي الموضعي) في مواضع الحقن. &nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تقم بحقن نفسك في نفس الموضع في كل مرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تقُم بالحقن حيث يكون الجلد فيه حفر أو سميكًا أو فيه كتل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; <strong>لا</strong> تقُم بالحقن حيث يكون الجلد حساسًا، به كدمات، متقشرًا أو قاسيًا، أو حيث تظهر عليه ندوب أو حيث يكون الجلد متضررًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال تفويت جرعة من لومجيف، راقب مستوى السكر في دمك لتقرّر ما إذا كنت بحاجة إلى جرعة من الإنسولين. وتابع جدول جرعاتك المعتاد اعتبارًا من الوجبة التالية.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفّر لومجيف في قارورة، أو في قلم مسبق التعبئة مخصّص للاستخدام من قبل مريض واحد، أو في خرطوشة. وينبغي <strong>الامتناع</strong> عن استخدام محقنة لسحب محلول لومجيف من القلم المسبق التعبئة المخصّص للاستخدام من قبل مريض واحد أو من الخرطوشة.&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>يوصى بإبقاء لومجيف وجميع الأدوية بعيدًا عن متناول الأطفال.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عند أخذ هذا الدواء، لا بدّ من الالتزام دائمًا بما هو وارد في هذه النشرة أو بتعليمات الطبيب أو الصيدلي أو الممرّض. وإذا لم تكن متأكّدًا، عليك استشارة الطبيب أو الصيدلي أو الممرّض. &nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يتعيّن تغيير جرعتك من لومجيف للأسباب التالية: </strong></p><p dir="RTL">تغيّر في مستوى النشاط البدني أو ممارسة الرياضة، زيادة الوزن أو خسارته، ازدياد التعرض للإجهاد، المرض، تغيّر في النظام الغذائي، أو بسبب الأدوية الأخرى التي تستخدمها.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال أخذ كمية من لومجيف تفوق الجرعة المحدّدة </strong></p><p dir="RTL">قد يؤدّي أخذ كمية مفرطة من الإنسولين إلى نقص سكّر الدّم ونقص بوتاسيوم الدّم. يُمكن علاج نوبات نقص سكّر الدّم الخفيفة عادة بواسطة الغلوكوز المأخوذ عن طريق الفم. وقد يتعيّن إجراء تعديلات على جرعات الأدوية، أو أنماط الوجبات، أو ممارسة الرياضة. أمّا النوبات الأشدّ التي تتخلّلها حالات غيبوبة أو نوبات صرعيّة أو اختلال عصبي، فيمكن معالجتها بواسطة الغلوكاغون أو محلول الغلوكوز المركّز عن طريق الوريد. قد يكون من الضروري أن يتناول المريض الكربوهيدرات بشكل مستمرّ وأن يخضع للمراقبة لأنّ نقص سكّر الدّم قد يتكرّر بعد التعافي السريري الظاهري. كما ينبغي معالجة نقص بوتاسيوم الدّم بالطريقة المناسبة.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تأخذ جرعتك من لومجيف</strong></p><p dir="RTL">لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقّفت عن استخدام لومجيف</strong></p><p dir="RTL">إذا كانت لديك أيّ أسئلة إضافيّة في ما يتعلّق باستخدام هذا الدواء، اسأل الطبيب أو الصيدلي أو الممرّض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات عامّة حول الاستخدام الآمن والفعّال للومجيف.</strong></p><p dir="RTL">توصف الأدوية أحيانًا لأغراض غير تلك المذكورة في نشرة معلومات المريض. يوصى بالامتناع عن استخدام لومجيف للحالات التي لم يوصف لها. كما ينبغي <strong>الامتناع</strong> عن إعطاء لومجيف للآخرين، حتّى وإن كانوا يعانون من أعراض مشابهة لأعراضك، لأنّه قد يُضرّ بهم.&nbsp; وبإمكانك أن تطلب من الصيدلي أو مقدّم الرعاية الصحية معلومات عن لومجيف موجّهة للعاملين في مجال الرعاية الصحية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، قد يسبّب هذا الدواء آثارًا جانبية، وإن لم تكن تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الآثار الجانبيّة المحتملة لدواء لومجيف؟</strong></p><p dir="RTL"><strong>قد يتسبّب لومجيف بآثار جانبية خطيرة يُمكن أن تؤدّي إلى الوفاة، بما في ذلك: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انخفاض مستوى السكّر في الدّم (نقص سكّر الدّم)</strong>. تشمل العلامات والأعراض التي قد تشير إلى انخفاض مستوى السكر في الدم: الدوخة أو الدوار، التعرّق، الارتباك، الصداع، الرؤية غير الواضحة، الكلام المتداخل، الارتجاف، تسارع ضربات القلب، الجوع، القلق، الانفعاليّة، أو تقلّبات المزاج. &nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>انخفاض مستوى البوتاسيوم في الدم (نقص بوتاسيوم الدّم).</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات تحسسية خطيرة (تفاعلات تحسسية في كامل الجسم). احصل على رعاية طبية طارئة مباشرة إذا عانيت من أيّ من أعراض التفاعلات التحسسية الشديدة التالية:</strong> طفح جلدي في كامل الجسم، صعوبة في التنفّس، تسارع في ضربات القلب، تورّم الوجه أو اللسان أو الحلق، تعرّق، أو شعور بالإغماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قصور القلب.</strong> قد يؤدّي أخذ بعض أدوية السكّري من فئة الثيازوليدينديونات (TZDs) بالتزامن مع لومجيف إلى إصابة بعض الأسخاص بقصور في القلب. قد يحدث هذا حتّى إذا لم يسبق لك أن عانيت من قصور في القلب أو من مشاكل مرتبطة بقصور القلب. إذا سبق لك أن تعرّضت لقصور في القلب، فإنّ وضعك قد يتفاقم أثناء استخدامك الثيازوليدينديونات بالتزامن مع لومجيف. على مقدّم الرعاية الصحية أن يتابعك عن كثب أثناء فترة استخدامك للثيازوليدينديونات بالتزامن مع لومجيف. أبلغ مقدّم الرعاية الصحية إذا عانيت من أعراض جديدة أو متفاقمة لقصور القلب، بما في ذلك: ضيق التنفس، تورّم الكاحلين أو الساقين، أو الزيادة المفاجئة في الوزن. قد يتعيّن على مقدّم الرعاية الصحية&nbsp; أن يعدّل علاجك بالثيازوليدينديونات بالتزامن مع لومجيف، أو أن يوقفه، في حال تعرّضك لقصور في القلب أو تفاقم القصور الذي تعاني منه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احصل على رعاية طبية طارئة إذا عانيت من: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفّس،&nbsp; ضيق في التنفس، تسارع في ضربات القلب، تورّم الوجه أو اللسان أو الحلق، تعرّق، دوار شديد، دوخة أو ارتباك.</p><p dir="RTL"><strong>تشمل الآثار الجانبية الأكثر شيوعًا لـلومجيف ما يلي:</strong></p><p dir="RTL">انخفاض مستوى السكّر في الدّم (نقص سكّر الدّم)، التفاعلات في موضع الحقن، التفاعلات التحسسية، الطفح الجلدي، الحكّة، ازدياد سماكة الجلد أو ظهور حفر (الحثل الشحمي) في موضع الحقن، وزيادة الوزن.&nbsp;</p><p dir="RTL"><strong>هذه ليست كلّ الآثار الجانبية المحتملة لـلومجيف.</strong> اتّصل بطبيبك للحصول على مشورة طبية بشأن الآثار الجانبية. كما يُمكنك الإبلاغ عن الآثار الجانبية عبر نظام الإبلاغ الوطني.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا شعرت بأيّ آثار جانبية، عليك التحدّث مع الطبيب أو الصيدلي أو الممرّض. ويشمل هذا أيّ آثار جانبية محتملة غير مدرجة في هذه النشرة. كما يمكنك الإبلاغ عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني . من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساهمة في توفير مزيد من المعلومات حول سلامة هذا الدواء.&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي :(NPC)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 7662-205-11-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رقم المركز: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن هذا الدواء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك واستهلاكه خلافاً للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب والصيدلي هما الخبيران في الدواء وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تترك الأدوية في متناول أيدي الأطفال.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr></tbody></table><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">واتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم.</p><p dir="RTL">تحفظ قوارير وأقلام وخراطيش لومجيف غير المفتوحة بين درجتين إلى 8 درجات مئوية (36 درجة فهرنهايت إلى 46 درجة فهرنهايت) حتى وقت الاستخدام ويحتفظ بها في العلبة الأصلية لحمايتها من الضوء. لا تجمد لومجيف أو تستخدمه إذا تم تجميده. لا تعرضه للحرارة المباشرة. تخلّص من القوارير والأقلام والخراطيش المفتوحة أو غير المفتوحة المخزنة في درجة حرارة الغرفة أقل من 30 درجة مئوية (86 درجة فهرنهايت) بعد 28 يومًا.</p><p dir="RTL">تمّ تلخيص شروط تخزين القوارير والأقلام والخراطيش في الجدول.2</p><p dir="RTL"><strong>الجدول </strong><strong>&nbsp;.2</strong><strong>شروط تخزين القوارير والأقلام والخراطيش</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الشكل الصيدلاني</strong><strong> </strong><strong>للومجيف</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>غير مستعملة </strong><strong>)</strong><strong>مغلقة</strong><strong>(</strong></p></td><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>قيد الاستعمال</strong><strong>) </strong><strong>مفتوحة</strong><strong>(</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>حرارة الغرفة </strong><strong>)</strong><strong>أقل من 30 درجة مئوية </strong><strong>]</strong><strong>86 درجة فهرنهايت</strong><strong>[</strong><strong>)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الثلاجة</strong><strong> </strong><strong>بين درجتين إلى 8 درجات مئوية (36 درجة فهرنهايت إلى 46 درجة فهرنهايت)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>حرارة الغرفة </strong><strong>)</strong><strong>أقل من 30 درجة مئوية </strong><strong>]</strong><strong>86 درجة فهرنهايت</strong><strong>[</strong><strong>)</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الثلاجة</strong><strong> </strong><strong>بين درجتين إلى 8 درجات مئوية (36 درجة فهرنهايت إلى 46 درجة فهرنهايت)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قارورة<sup>أ،</sup><sup> </sup><sup>ب</sup> 10 مل</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">حتى تاريخ انتهاء الصلاحية</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">خرطوشة<sup> ب</sup> 3 مل</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">حتى تاريخ انتهاء الصلاحية</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">لا تبرد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لومجيف 3 مل<strong> </strong>كويك بن</p><p dir="RTL">&nbsp;U-200)و( U-100 <sup>ب</sup></p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">حتى تاريخ انتهاء الصلاحية</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">لا تبرد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لومجيف 3 مل<strong> </strong>جونيور<strong> </strong>كويك بن<sup> ب</sup></p><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">حتى تاريخ انتهاء الصلاحية</p></td><td style="vertical-align:top"><p dir="RTL">28 يومًا</p></td><td style="vertical-align:top"><p dir="RTL">لا تبرد</p></td></tr></tbody></table><p dir="RTL"><sup>أ</sup> يجب استخدام القوارير (المفتوحة) المستخدمة، سواء كانت في الثلاجة أم لا، في غضون 28 يوماً.</p><p dir="RTL"><sup>ب</sup> عند تخزينه في درجة حرارة الغرفة، يمكن استخدام لومجيف لمدة 28 يومًا فقط ويشمل هذا وقت التخزين قبل )العلبة مغلقة( وقيد )العلبة مفتوحة( الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يبقى المحلول مستقراً حتى 14 يومًا عند تخفيفه إلى تركيزات من 0.1 إلى 1 وحدة / مل في حقنة 5٪ دكستروز أو حقنة 0.9٪ كلوريد الصوديوم عند تخزينه في الثلاجة تحت درجة حرارة 2 إلى 8 درجات مئوية [36 إلى 46 درجة فهرنهايت] حتى وقت الاستخدام. يمكن تخزين نفس الحلول لمدة تصل إلى 20 ساعة في درجة حرارة الغرفة عند 20&nbsp; إلى 25 درجة مئوية [(68 إلى 77 درجة فهرنهايت)].</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي الامتناع عن استخدام هذا الدواء بعد تاريخ انتهاء صلاحيته المحدّد على العلبة بعد {المختصر المستخدم للإشارة إلى تاريخ انتهاء الصلاحية}. ويُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي الامتناع عن رمي أيّ أدوية في مياه الصرف الصحي أو مع النفايات المنزلية، واستشارة الصيدلي حول كيفية التخلّص من الأدوية التي توقّفت عن استخدامها. من شأن هذه التدابير المساهمة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات لومجيف</strong></p><p dir="RTL">المادة الفعالة هي الإنسولين ليسبرو</p><p dir="RTL">المكوّنات الأخرى هي: الغليسيرول، سداسي هيدرات كلوريد المغنيسيوم، الميتاكريزول، سيترات الصوديوم ثنائي الهيدرات، تريبروستينيل الصوديوم، أكسيد الزّنك (أيون الزنك)، والماء للحقن، USP.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لومجيف هو عبارة عن محلول شفاف وعديم اللون، مُتوفر كما هو مبين في الجدول</strong><strong>.3 </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong><strong>الجدول</strong><strong> .3 </strong><strong>كيفية توفّره</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>لومجيف</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>التركيز</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>مجموع الوحدات في الشكل الصيدلاني</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>زيادة الجرعة</strong></p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>حجم العبوة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;U-100قارورة 10 مل متعددة الجرعات</p></td><td><p dir="RTL"><strong>&nbsp;</strong>100&nbsp; وحدة /مل</p></td><td><p dir="RTL">1,000 وحدة</p></td><td><p dir="RTL">لا ينطبق</p></td><td><p dir="RTL">قارورة واحدة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;U-100خرطوشة<sup>أ</sup> 3 مل للاستخدام من طرف مريض واحد</p></td><td><p dir="RTL">&nbsp;100وحدة /مل</p></td><td><p dir="RTL">300 وحدة</p></td><td><p dir="RTL">لا ينطبق</p></td><td><p dir="RTL"><strong>&nbsp;</strong>5<strong> </strong>خراطيش</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;U-100 كويك بن 3 مل للاستخدام من طرف مريض واحد</p></td><td><p dir="RTL">&nbsp;100وحدة /مل</p></td><td><p dir="RTL">300 وحدة</p></td><td><p dir="RTL">وحدة واحدة</p></td><td><p dir="RTL">&nbsp;5أقلام</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;U-100كويك بن 3 مل للاستخدام من طرف مريض واحد</p></td><td><p dir="RTL">&nbsp;100 وحدة /مل</p></td><td><p dir="RTL">300 وحدة</p></td><td><p dir="RTL"><strong>&nbsp;</strong>0.5 وحدة</p></td><td><p dir="RTL">&nbsp;5أقلام</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;U-200&nbsp;&nbsp; كويك بن 3 مل للاستخدام من طرف مريض واحد</p></td><td><p dir="RTL">&nbsp;200 وحدة /مل</p></td><td><p dir="RTL">600 وحدة</p></td><td><p dir="RTL">وحدة واحدة</p></td><td><p dir="RTL">&nbsp;5 أقلام</p></td></tr></tbody></table><p dir="RTL"><sup>أ</sup> خرطوشة 3 مل هي&nbsp; للاستخدام في أجهزة حقن الإنسولين لشركة إيلي ليلي و شركاه&nbsp;</p><p dir="RTL">يحتاج المرضى إلى التحقق من دليل جهازهم لتحديد ما إذا كانت خرطوشة لومجيف متوافقة للاستخدام في أجهزة أخرى.</p><p dir="RTL">قد لا تكون جميع أحجام العبوات متوفرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق والمصنّع</strong></p><p dir="RTL">شركة إيلي ليلي وشركاه، إنديانابوليس، IN 46285، الولايات المتّحدة الأمريكية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أيّ معلومات تتعلّق بهذا الدواء، يُرجى الاتصال بالممثل المحلّي لحامل ترخيص التسويق:</p><p dir="RTL">شركة إيلي ليلي آند كومباني- المملكة العربية السعودية</p><p dir="RTL">ص.ب92120 :</p><p dir="RTL">الطابق16 ، مبنى رقم 3074</p><p dir="RTL">برج ب، أبراج العُليَّا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العُليَّا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر+966114617850 ،&nbsp; +966114617800</p><p dir="RTL">الفاكس&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966112179900 :</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تم  مراجعة نشرة المريض هذه في أغسطس 2021   
النسخة 3

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

LYUMJEV injection: 100 units/mL (U-100) available as:
•	LYUMJEV 100 units/mL 10 mL multiple-dose vial 
•	LYUMJEV 100 units/mL 3 mL single-patient-use KwikPen 
•	LYUMJEV 100 units/mL 3 mL single-patient-use Junior KwikPen 

LYUMJEV injection: 200 units/mL (U-200) available as:
•	LYUMJEV 200 units/mL 3 mL single-patient-use KwikPen 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	General description

Insulin lispros a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro- is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808 daltons, both identical to that of human insulin.
Insulin lispro has the following primary structure: 

 

LYUMJEV (insulin lispro) injection is a sterile, aqueous, clear, and colorless solution for subcutaneous or intravenous administration. Each mL of LYUMJEV U-100 contains 100 units of insulin lispro and the inactive ingredients: glycerol (12.1 mg), magnesium chloride hexahydrate (1.02 mg), metacresol (3.15 mg), sodium citrate dihydrate (4.41 mg), treprostinil sodium (1.06 mcg), zinc oxide (content adjusted to provide 39 mcg zinc ion), and Water for Injection, USP.

2.2	Qualitative and quantitative composition

Each mL of LYUMJEV U-200 contains 200 units of insulin lispro and the inactive ingredients: glycerol (12.1 mg), magnesium chloride hexahydrate (1.02 mg), metacresol (3.15 mg), sodium citrate dihydrate (4.41 mg), treprostinil sodium (1.06 mcg), zinc oxide (content adjusted to provide 52 mcg zinc ion), and Water for Injection, USP.
Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH. LYUMJEV has a pH of 7.0 to 7.8.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injection:  100 units per mL (U-100) clear and colorless solution available as:
•	10 mL multiple-dose vial
•	3 mL single-patient-use LYUMJEV KwikPen
•	3 mL single-patient-use LYUMJEV Junior KwikPen
Injection:  200 units per mL (U-200) clear and colorless solution available as:
•	3 mL single-patient-use LYUMJEV KwikPen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LYUMJEV&trade; is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Important Administration Instructions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Always check insulin labels before administration <em>[see Special Warnings and Precautions for Use (4.4)]</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inspect LYUMJEV visually before use. It should appear clear and colorless. Do not use LYUMJEV if particulate matter and discoloration is seen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not perform dose conversion when using any LYUMJEV U-100 or U-200 prefilled pens. The dose window of LYUMJEV prefilled pens shows the number of units of LYUMJEV to be injected.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not transfer LYUMJEV U-200 from the prefilled pen to a syringe for administration <em>[see Special Warnings and Precautions for Use (4.4)]</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Use LYUMJEV prefilled pens with caution in patients with visual impairment that may rely on audible clicks to dial their dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not mix LYUMJEV with any other insulin products.</p><p>Route of Administration Instructions</p><p>Subcutaneous Injection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Administer LYUMJEV at the start of a meal or within 20&nbsp;minutes after starting a meal subcutaneously into the abdomen, upper arm, thigh, or buttocks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis <em>[see Undesirable Effects (4.8)].</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; LYUMJEV given by subcutaneous injection should generally be used in regimens with intermediate or long-acting insulin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; The LYUMJEV U-100 KwikPen, and LYUMJEV U-200 KwikPen each dial in 1&nbsp;unit increments and deliver a maximum dose of 60&nbsp;units per injection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; The LYUMJEV U-100 Junior KwikPen dials in 0.5&nbsp;unit increments and delivers a maximum dose of 30&nbsp;units per injection.</p><p>Intravenous Administration for LYUMJEV U-100 Only</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not administer LYUMJEV U-200 intravenously.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Administer LYUMJEV U-100 intravenously only under medical supervision with close monitoring of glucose and potassium levels to avoid hypoglycemia and hypokalemia <em>[see Special Warnings and Precautions for Use (4.4)]</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Dilute LYUMJEV U-100 to a concentration of 1&nbsp;unit/mL using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP infusion solutions. Dilutions to concentrations below 1 unit/mL are not recommended.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Stable up to 14 days when diluted to concentrations of 0.1 to 1 U/mL in 5% Dextrose Injection or 0.9% Sodium Chloride Injection when stored in a refrigerator at 2&deg;C to 8&deg;C [36&deg;F to 46&deg;F] until time of use. The same solutions may be stored for up to 20 hours at room temperature at 20&deg;C to 25&deg;C [(68&deg;F to 77&deg;F)].</p><p>General Dosage Instructions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Individualize and adjust the dosage of LYUMJEV based on the patient&rsquo;s metabolic needs, glucose monitoring results, and glycemic control goal.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; If converting from another mealtime insulin to LYUMJEV, the change can be done on a unit-to-unit basis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Dosage adjustments may be needed when switching from another insulin, with changes in physical activity, changes in concomitant medications, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness to minimize the risk of hypoglycemia or hyperglycemia <em>[see Special Warnings and Precautions For Use (4.4), Interactions with other medicinal products and other forms of interaction (4.5) and Use in Specific Populations (5.2)].</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; During changes to a patient&rsquo;s insulin regimen, increase the frequency of glucose monitoring <em>[see Special Warnings and Precautions For Use (4.4)].</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Instruct patients who forget a mealtime dose to monitor their glucose level to decide if an insulin dose is needed, and to resume their usual dosing schedule at the next meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LYUMJEV is contraindicated:
•	during episodes of hypoglycemia.
•	in patients with hypersensitivity to insulin lispro or one of the excipients in LYUMJEV.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Never Share a LYUMJEV Prefilled Pen, Cartridge, or Syringe Between Patients</p><p>LYUMJEV prefilled pens or cartridges should never be shared between patients, even if the needle is changed. Patients using LYUMJEV vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.</p><p>Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen</p><p>Changes in an insulin regimen (e.g., insulin, insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia <em>[see Special Warnings and Precautions For Use (4.4)]</em> or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to an unaffected area) has been reported to result in hypoglycemia <em>[see Undesirable Effects (</em><em>4</em><em>.8)]</em>.</p><p>Make any changes to a patient&#39;s insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.</p><p>Hypoglycemia</p><p>Hypoglycemia is the most common adverse reaction associated with insulins, including LYUMJEV <em>[see Undesirable Effects (</em><em>4</em><em>.8)]</em>. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). LYUMJEV, or any insulin, should not be used during episodes of hypoglycemia <em>[see Contraindications (4.3)]</em>.</p><p>Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) <em>[see Interactions with other medicinal products and other forms of interaction (4.5)]</em>, or in patients who experience recurrent hypoglycemia.</p><p>Risk Factors for Hypoglycemia</p><p>The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose lowering effect of the insulin is maximal. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulation. As with all insulin preparations, the glucose lowering effect time course of LYUMJEV may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature <em>[see Pharmacodynamic Properties (5.1)].</em> Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to co-administered medication <em>[see Interactions with other medicinal products and other forms of interaction (4.5)]</em>. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia <em>[see Use in Specific Populations (5.2)].</em></p><p>Risk Mitigation Strategies for Hypoglycemia</p><p>Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of glucose monitoring is recommended.</p><p>Hypoglycemia Due to Medication Errors</p><p>Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between LYUMJEV and other insulins, instruct patients to always check the insulin label before each injection.</p><p>Do not transfer LYUMJEV U-200 from the LYUMJEV KwikPen to a syringe. The markings on the insulin syringe will not measure the dose correctly and can result in overdosage and severe hypoglycemia <em>[</em><em>see Posology and method of administration </em><em>(</em><em>4.2</em><em>) and Special Warnings and Precautions For Use (4.4)]</em>.</p><p>Hypokalemia</p><p>All insulin products, including LYUMJEV, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).</p><p>Hypersensitivity and Allergic Reactions</p><p>Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including LYUMJEV <em>[see Undesirable Effects (</em><em>4</em><em>.8)]</em>. If hypersensitivity reactions occur, discontinue LYUMJEV; treat per standard of care and monitor until symptoms and signs resolve. LYUMJEV is contraindicated in patients who have had hypersensitivity reactions to insulin lispro or any of its excipients <em>[see Contraindications (</em><em>4</em><em>.2)]</em>.</p><p>Fluid Retention and Heart Failure with Concomitant Use of PPAR-Gamma Agonists</p><p>Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including LYUMJEV, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Table 1 includes clinically significant drug interactions with LYUMJEV.</p><p>&nbsp;</p><p>Table 1. Clinically Significant Drug Interactions with LYUMJEV</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>Drugs That May Increase the Risk of Hypoglycemia</strong></p></td></tr><tr><td><p><strong>Drugs:</strong></p></td><td><p>Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.</p></td></tr><tr><td><p><strong>Intervention:</strong></p></td><td><p>Dose reductions and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr><tr><td colspan="2"><p><strong>Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV</strong></p></td></tr><tr><td><p><strong>Drugs:</strong></p></td><td><p>Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.</p></td></tr><tr><td><p><strong>Intervention:</strong></p></td><td><p>Dose increases and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr><tr><td colspan="2"><p><strong>Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LYUMJEV</strong></p></td></tr><tr><td><p><strong>Drugs:</strong></p></td><td><p>Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.</p></td></tr><tr><td><p><strong>Intervention:</strong></p></td><td><p>Dose adjustment and increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr><tr><td colspan="2"><p><strong>Drugs That May Blunt Signs and Symptoms of Hypoglycemia</strong></p></td></tr><tr><td><p><strong>Drugs:</strong></p></td><td><p>Beta-blockers, clonidine, guanethidine, and reserpine.</p></td></tr><tr><td><p><strong>Intervention:</strong></p></td><td><p>Increased frequency of glucose monitoring may be required when LYUMJEV is co-administered with these drugs.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Risk Summary</p><p>Published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes <em>(see Data).</em> There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <em>(see Clinical Considerations). </em>Pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. No adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3&nbsp;times the human subcutaneous dose of 1&nbsp;unit insulin lispro/kg/day. No adverse effects on embryo/fetal development were observed in offspring of rabbits exposed to insulin lispro at doses up to approximately 0.2&nbsp;times the human subcutaneous dose of 1&nbsp;unit/kg/day <em>(see Data).</em></p><p>The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a HbA<sub>1c</sub>&gt;7 and has been reported to be as high as 20% to 25% in women with a HbA<sub>1c</sub>&gt;10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p>Clinical Considerations</p><p><em>Disease-associated Maternal and/or Embryo-Fetal Risk</em></p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.</p><p>Data</p><p>Human Data</p><p>Published data from retrospective studies and meta-analyses do not report an association with insulin lispro and major birth defects, or adverse maternal or fetal outcomes when insulin lispro is used during pregnancy. However, these studies cannot definitely establish or exclude the absence of any risk because of methodological limitations including small sample size, selection bias, confounding by unmeasured factors, and some lacking comparator groups.</p><p>Animal Data</p><p>Animal reproduction studies have not been performed with LYUMJEV. However, subcutaneous reproduction and teratology studies have been conducted with insulin lispro. In a combined fertility and embryo-fetal development study, female rats were given subcutaneous insulin lispro injections of 1, 5, and 20&nbsp;units/kg/day (0.2, 0.8, and 3&nbsp;times the human subcutaneous dose of 1&nbsp;unit insulin lispro/kg/day, based on units/body surface area, respectively) from 2&nbsp;weeks prior to cohabitation through Gestation Day 19. There were no adverse effects on female fertility, implantation, or fetal viability and morphology. However, fetal growth retardation was produced at the 20&nbsp;units/kg/day-dose as indicated by decreased fetal weight and an increased incidence of fetal runts/litter.</p><p>In an embryo-fetal development study in pregnant rabbits, insulin lispro doses of 0.1, 0.25, and 0.75&nbsp;unit/kg/day (0.03, 0.08, and 0.2&nbsp;times the human subcutaneous dose of 1&nbsp;unit insulin lispro/kg/day, based on units/body surface area, respectively) were injected subcutaneously on Gestation Days 7 through 19. There were no adverse effects on fetal viability, weight, and morphology at any dose.</p><p>Lactation</p><p>Risk Summary</p><p>Available data from published literature suggests that exogenous human insulin products, including insulin lispro, are transferred into human milk. There are no adverse reactions reported in breastfed infants in the literature. There are no data on the effects of exogenous human insulin products, including insulin lispro, on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for insulin, any potential adverse effects on the breastfed child from LYUMJEV or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The proper use of the correct therapeutic dose of insulins has no known effect on driving or the use of machinery. The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are also discussed elsewhere:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Hypoglycemia <em>[see Special Warnings and Precautions For Use (4.4)].</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Hypokalemia <em>[see Special Warnings and Precautions For Use (4.4)]</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity and Allergic Reactions <em>[see Special Warnings and Precautions For Use (4.4)].</em></p><p>&nbsp;</p><p><strong>Clinical Trial Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates actually observed in clinical practice.</p><p>The data in Table 2 reflect the exposure of 780 adult patients with type 1 diabetes to LYUMJEV with a mean exposure duration of 26&nbsp;weeks <em>[see </em><em>Pharmacodynamic</em><em> Properties (5.1)].</em> The mean age was 44&nbsp;years, the mean duration of diabetes was 19&nbsp;years, 55% were male, 77% were White, 2% were Black or African American, and 9% were Hispanic. The mean BMI was 26.6&nbsp;kg/m<sup>2</sup> and the mean HbA<sub>1c</sub> at baseline was 7.3%.</p><p>The data in Table 3 reflect the exposure of 336 adult patients with type 2 diabetes to LYUMJEV with a mean exposure duration of 26&nbsp;weeks <em>[</em><em>Pharmacodynamic</em><em> Properties (5.1)]</em>. The mean age was 60&nbsp;years, the mean duration of diabetes was 16&nbsp;years, 55% were male, 69% were White, 4% were Black or African American, and 24% were Hispanic. The mean BMI was 32.1&nbsp;kg/m<sup>2</sup> and the mean HbA<sub>1c</sub> at baseline was 7.3%.</p><p>The data in Table 4 reflect the exposure of 418 pediatric patients with type 1 diabetes to LYUMJEV with a mean exposure duration of 26 weeks <em>[see Clinical Studies (5.1]</em>. The mean age was 12 years, the mean duration of diabetes was 5 years, 50% were male, 91% were White, 1% were Black or African American, and 23% were Hispanic. The mean BMI was 20.5 kg/m2 and the mean HbA1c at baseline was 7.8%.</p><p>The data in Table 5 reflect the exposure of 215 adult patients with type 1 diabetes to LYUMJEV via CSII administration with a mean exposure duration of 16 weeks <em>[</em><em>see Clinical Studies</em><em> (5.1)]</em>. The mean age was 48&nbsp;years, the mean duration of diabetes was 26&nbsp;years, 44% were male, 94% were White, 3% were Black or African American, and 8% were Hispanic. The mean BMI was 27.0&nbsp;kg/m<sup>2</sup> and the mean HbA<sub>1c</sub> at baseline was 7.6%.</p><p>Common adverse reactions, excluding hypoglycemia, were defined as events occurring in &ge;5% and occurring at the same rate or greater for LYUMJEV-treated patients than HUMALOG<sup>&reg;</sup>-treated patients.</p><p>&nbsp;</p><p>Table 2. Adverse Reactions Occurring in &ge;5% of LYUMJEV-Treated Adult Patients with Type 1 Diabetes</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV + basal insulin</strong></p><p>(N=451)</p><p>%</p></td><td style="vertical-align:top"><p><strong>Postmeal LYUMJEV + basal insulin</strong></p><p><strong>(N=329)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>14.2</p></td><td style="vertical-align:top"><p>14.6</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 3. Adverse Reactions Occurring in &ge;5% of LYUMJEV-Treated Adult Patients with Type 2 Diabetes</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV + basal insulin</strong></p><p>(N=336)</p><p>%</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>12.5</p></td></tr><tr><td style="vertical-align:top"><p>Upper Respiratory Tract Infection</p></td><td style="vertical-align:top"><p>7.4</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 4. Adverse Reactions Occurring in &ge;5% of LYUMJEV-Treated Pediatric Patients with Type 1 Diabetes</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV + basal insulin </strong></p><p><strong>(N=280) </strong></p><p>%</p></td><td style="vertical-align:top"><p><strong>Postmeal LYUMJEV + basal insulin </strong></p><p><strong>(N=138) </strong></p><p>%</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>8.2</p></td><td style="vertical-align:top"><p>5.1</p></td></tr><tr><td style="vertical-align:top"><p>Upper Respiratory Tract Infection</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>1.4</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 5. Adverse Reactions Occurring in &ge;5% of LYUMJEV-Treated Adult Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion</p><table border="0" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>CSII LYUMJEV administration</strong></p><p><strong>(N=215)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infusion site reaction</p></td><td style="vertical-align:top"><p>19.1</p></td></tr><tr><td style="vertical-align:top"><p>Infusion site pain</p></td><td style="vertical-align:top"><p>15.8</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>6.0</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Hypoglycemia</p><p>Hypoglycemia is the most commonly observed adverse reaction in patients using insulin, including LYUMJEV. The rates of reported hypoglycemia depend on the definition of hypoglycemia used, diabetes type, insulin dose, intensity of glucose control, background therapies, and other intrinsic and extrinsic patient factors. For these reasons, comparing rates of hypoglycemia in clinical trials for LYUMJEV with the incidence of hypoglycemia for other products may be misleading and also may not be representative of hypoglycemia rates that occur in clinical practice.</p><p>Incidence rates for severe hypoglycemia in adults with type 1 and type 2 diabetes mellitus and pediatric patients with type 1 diabetes mellitus treated with LYUMJEV in clinical trials are shown in Table 6 <em>[See Pharmacodynamic Properties (5.1)].</em></p><p>&nbsp;</p><p>Table 6. Proportion of Patients with Type 1 Diabetes and Type 2 Diabetes Experiencing at Least One Episode of Severe Hypoglycemia in Adult and Pediatric Clinical Trials</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>PRONTO-T1D (Adult Type 1)</strong></p></td><td style="vertical-align:top"><p><strong>PRONTO-T2D (Adult Type 2)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PRONTO-Peds (Pediatric Type 1) </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>PRONTO-Pump-2 (Adult Type 1 CSII)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV +</strong></p><p>basal insulin</p><p>(N=451)</p><p>%</p></td><td style="vertical-align:top"><p><strong>Postmeal LYUMJEV +</strong></p><p><strong>basal insulin</strong></p><p>(N=329)</p><p>%</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV +</strong></p><p>basal insulin</p><p>(N=336)</p><p>%</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV + basal insulin </strong></p><p><strong>(N=280) </strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Postmeal LYUMJEV + basal insulin </strong></p><p><strong>(N=298) </strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>LYUMJEV</strong></p><p><strong>(N=215)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe hypoglycemia<sup>a</sup></p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>1.4</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Severe hypoglycemia: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions</p><p>&nbsp;</p><p>Allergic Reactions</p><p>Severe, life-threatening, generalized allergy, including anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, and shock may occur with any insulin, including LYUMJEV, and may be life threatening. Generalized hypersensitivity reactions such as skin rashes and hypersensitivity were reported in patients treated with LYUMJEV: eczema (0.4%), rash (0.4%), dermatitis (0.3%), hypersensitivity (0.2%), and pruritus (0.2%).</p><p>Lipodystrophy</p><p>Administration of insulin, including LYUMJEV, has resulted in lipohypertrophy (enlargement or thickening of tissue) and lipoatrophy (depression in the skin). Lipodystrophy was reported in 0.2% of patients treated with LYUMJEV <em>[see Posology and method of administration (4.2)]</em>.</p><p>Injection/Infusion Site Reactions</p><p>Injection or infusion site reactions can occur with insulin therapy. With LYUMJEV, patients have experienced rash, redness, inflammation, pain, bruising, or itching at the site of LYUMJEV injection or infusion. LYUMJEV contains treprostinil sodium and sodium citrate dihydrate as inactive ingredients <em>[see DESCRIPTION (2.1)]</em> which have been associated with infusion and injection site reactions with other non-insulin products.</p><p><em>Subcutaneous Injection Site-Related Reactions</em>:</p><p>In studies PRONTO-T1D and PRONTO-T2D, injection site-related reactions occurred in 2.7% of patients treated with LYUMJEV (mild in 2.2% and moderate in 0.5%) with &lt;0.1% of patients discontinuing from treatment due to injection site-related reactions.</p><p>In Study PRONTO-Peds, injection site-related reactions occurred in 6.2% of patients treated with LYUMJEV (mild in 5.7% and moderate in 0.5%), with &lt;0.5% of patients discontinuing from treatment due to injection site-related reactions.</p><p>Continuous Subcutaneous Insulin Infusion (CSII) Site-Related Reactions:</p><p>In Study PRONTO-Pump-2, infusion site-related reactions were reported in 37.7% of patients treated with LYUMJEV (mild in 27.9%, moderate in 7.9%, and severe in 1.9%), with 3.3% of patients discontinuing from treatment due to infusion site-related reactions. See Table 5.</p><p>Weight Gain</p><p>Weight gain can occur with insulin therapy, including LYUMJEV, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria. Patients with type 1 diabetes treated with LYUMJEV gained an average of 0.6 kg and patients with type 2 diabetes treated with LYUMJEV gained an average of 1.5 kg.</p><p>Peripheral Edema</p><p>Insulin, including LYUMJEV, may cause sodium retention and edema, particularly if previous poor metabolic control is improved by intensified insulin therapy. Peripheral edema occurred in 0.2% of patients treated with LYUMJEV.</p><p>Immunogenicity</p><p>As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying disease. For these reasons, comparison of the incidence of antibodies to LYUMJEV in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</p><p>In a 26-week study in type 1 diabetes patients, 49% were anti-drug (insulin lispro) antibody (ADA)-positive at baseline, 91% of which were cross-reactive with native insulin. A total of 33% of LYUMJEV-treated patients had treatment-emergent ADA post-baseline (i.e., either new ADA or a 57% increase in assay signal over baseline), 75% of which were cross-reactive with native insulin.</p><p>In a 26-week study in type 2 diabetes patients, 35% were ADA-positive at baseline, 81% of which were cross-reactive with native insulin. A total of 31% of LYUMJEV-treated patients had treatment-emergent ADA post-baseline (i.e., either new ADA or a 57% increase in assay signal over baseline), 68% of which were cross-reactive with native insulin.</p><p>Presence of antibody did not correlate with reduced efficacy, as measured by HbA<sub>1c</sub>, or specific adverse reactions.</p><p>Postmarketing Experience</p><p>The following additional adverse reactions have been identified during post-approval use of insulin lispro. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>Localized cutaneous amyloidosis at the injection site has occurred with insulin use. Hyperglycemia has been reported with repeated insulin injections into areas of localized cutaneous amyloidosis; hypoglycemia has been reported with a sudden change to an unaffected injection site.</p><p>Pediatric Use</p><p>The safety and effectiveness of LYUMJEV in pediatric patients have been established to improve glycemic control in pediatric patients with diabetes mellitus. Use of LYUMJEV for this indication is supported by evidence from an adequate and well-controlled study in 716 pediatric patients with type 1 diabetes mellitus aged 1 to 17 years, and from clinical pharmacology studies in adult and pediatric patients with diabetes mellitus.</p><p>Other special population</p><p><u>Geriatric Use</u></p><p>In clinical trials, 187 of 1116&nbsp;(16.8%) LYUMJEV-treated patients with type 1 or type 2 diabetes were &ge;65&nbsp;years of age and 18 of 1116&nbsp;(1.6%) were &ge;75 years of age. No overall differences in safety or effectiveness were observed between these elderly patients and younger adult patients.</p><p><u>Renal Impairment</u></p><p>Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent LYUMJEV dose adjustment and more frequent glucose monitoring <em>[see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)]</em>.</p><p><u>Hepatic Impairment</u></p><p>Patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent LYUMJEV dose adjustment and more frequent glucose monitoring <em>[see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)]</em>.</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed here.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; SFDA Call Center: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excess insulin administration may cause hypoglycemia and hypokalemia <em>[see Special Warnings and Precautions For Use (4.4)]</em>. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise, may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: {Insulins and analogues for injection, fast-acting}, ATC code: {A10AB04}</p><p>&nbsp;</p><p>Mechanism of Action</p><p>The primary activity of LYUMJEV is the regulation of glucose metabolism. Insulins, including insulin lispro, exert their specific action through binding to insulin receptors. Receptor-bound insulin lowers glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.</p><p>Pharmacodynamics</p><p>The time course of insulin action (i.e., glucose lowering) may vary considerably in different individuals or within the same individual. The average pharmacodynamic profile [i.e., glucose lowering effect measured as glucose infusion rate (GIR) in a euglycemic clamp study] for subcutaneous administration of 7, 15, and 30 units of LYUMJEV in 42 healthy subjects is shown in Figure 1 and key characteristics of the timing of the effect are described in Table 7 below.</p><p><img alt="" width="528" height="408" src="data:image/png;base64,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" /></p><p>Figure 1. Mean Insulin Effect Over Time After Subcutaneous Administration of 7, 15, and 30 units of LYUMJEV in Healthy Subjects.</p><p>&nbsp;</p><p><strong>Table 7. Timing of Insulin Effect (i.e., Mean Pharmacodynamic Effect) After Subcutaneous Administration of 7, 15, and 30 Units of LYUMJEV in Healthy Subjects (N=42) and Corresponding to the Data Shown in Figure 1</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p><strong>Parameter for Insulin Effect</strong></p></td><td><p><strong>LYUMJEV</strong></p><p><strong>7 units</strong></p></td><td><p><strong>LYUMJEV</strong></p><p><strong>15 units</strong></p></td><td><p><strong>LYUMJEV</strong></p><p><strong>30 units</strong></p></td></tr><tr><td><p>Time to first measurable effect</p></td><td><p>~17 minutes</p></td><td><p>~17 minutes</p></td><td><p>~15 minutes</p></td></tr><tr><td><p>Time to peak effect</p></td><td><p>~120 minutes</p></td><td><p>~138 minutes</p></td><td><p>~174 minutes</p></td></tr><tr><td><p>Time for effect to return to baseline</p></td><td><p>~4.6 hours</p></td><td><p>~6.2 hours</p></td><td><p>~7.3 hours</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>On average, the pharmacodynamic effects of LYUMJEV, measured as area under the glucose infusion rate-time curve (AUC<sub>GIR</sub>), was 1080&nbsp;mg/kg, 1860&nbsp;mg/kg, and 3030&nbsp;mg/kg following administration of 7, 15, and 30&nbsp;units of LYUMJEV in healthy subjects.</p><p>Similar pharmacodynamic profiles were observed in separate studies conducted in 40 patients with type 1 diabetes and 38&nbsp;patients with type 2 diabetes given LYUMJEV subcutaneously as a single 15&nbsp;unit dose.</p><p>The onset and total glucose lowering were similar when LYUMJEV was administered in the abdomen, deltoid, or thigh. The day-to-day variability [percent coefficient of variation (CV%)] within subjects in the glucose-lowering-effect of LYUMJEV was 24% for the early glucose lowering (AUC<sub>GIR</sub>, 0-1h), 27% for the total glucose lowering (AUC<sub>GIR</sub>, 0-10h), and 19% for maximum glucose lowering effect (GIR<sub>max</sub>).</p><p>Postprandial Glucose Lowering</p><p>When given at the start of a meal or 20&nbsp;minutes after the start of the meal, LYUMJEV reduced postprandial glucose during a standardized test meal over the complete 5-hour period [change from premeal AUC(0-5h)] in patients with type 1 or type 2 diabetes.</p><p>The maximum and total glucose lowering were comparable for a single 15&nbsp;unit dose of LYUMJEV 200 units/mL or LYUMJEV 100&nbsp;units/mL when administered subcutaneously to healthy subjects. The insulin time action profile with LYUMJEV 200&nbsp;units/mL was the same as observed with LYUMJEV 100&nbsp;units/mL.</p><p>&nbsp;</p><p><strong>Clinical efficacy and safety</strong></p><p>CLINICAL STUDIES</p><p>Overview of Clinical Studies</p><p>The safety and efficacy of LYUMJEV was evaluated in 2 randomized, active controlled trials of 26&nbsp;weeks in adult patients with type 1 diabetes (N=780) or type 2 diabetes (N=336).</p><p>Type 1 Diabetes &ndash; Adults</p><p>PRONTO-T1D (NCT03214367) was a 26&nbsp;week, randomized (4:4:3), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 1222&nbsp;patients with type 1 diabetes. Patients were randomized to either blinded mealtime LYUMJEV (N=451), blinded mealtime HUMALOG (N=442), or open-label postmeal LYUMJEV (N=329), all in combination with either insulin glargine or insulin degludec. Mealtime LYUMJEV or HUMALOG was injected 0 to 2&nbsp; minutes before the meal and postmeal LYUMJEV was injected 20&nbsp;minutes after the start of the meal.</p><p>Patients had a mean age of 44&nbsp;years; mean duration of diabetes of 19 years; 56% were male; race: 77% White, 19% Asian, and 2% Black or African American. Eight percent of the randomized patients were Hispanic. The mean BMI was 26.6&nbsp;kg/m<sup>2</sup>.</p><p>At week 26, treatment with mealtime LYUMJEV provided a mean reduction in HbA<sub>1c</sub> that met the pre-specified non-inferiority margin (0.4%) (see Table 8). In addition, postmeal LYUMJEV met the prespecified non-inferiority margin (0.4%) compared to mealtime HUMALOG. Insulin doses were similar in all treatment groups at baseline and at 26&nbsp;weeks.</p><p>&nbsp;</p><p>Table 8. Results from Study PRONTO-T1D: 26&nbsp;Week Trial of Mealtime LYUMJEV and Postmeal LYUMJEV compared with Mealtime HUMALOG, all in Combination with Basal Insulin in Adults with Type 1 Diabetes</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Mealtime LYUMJEV + basal insulin</p></td><td><p>Mealtime HUMALOG + basal insulin</p></td><td><p>Postmeal LYUMJEV + basal insulin</p></td></tr><tr><td><p>Number of randomized subjects (N)</p></td><td><p>451</p></td><td><p>442</p></td><td><p>329</p></td></tr><tr><td colspan="4"><p>HbA<sub>1c</sub> (%) (mean)<sup>a,b</sup></p></td></tr><tr><td><p>&nbsp; Baseline</p></td><td><p>7.3</p></td><td><p>7.3</p></td><td><p>7.4</p></td></tr><tr><td><p>&nbsp; Adjusted mean change from baseline</p></td><td><p>-0.12</p></td><td><p>-0.04</p></td><td><p>0.1</p></td></tr><tr><td><p>&nbsp; Estimated treatment difference versus HUMALOG [95% CI]</p></td><td><p><sup>&nbsp;</sup>-0.08 [-0.16, 0.00]<sup>c</sup></p></td><td><p>&nbsp;</p></td><td><p>0.14 [0.05, 0.22]</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 26 were imputed by return to baseline approach. At week 26, primary efficacy assessment was missing for 3.8%, 4.8%, and 5.2% of subjects, for mealtime LYUMJEV, mealtime HUMALOG, and postmeal LYUMJEV, respectively.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; Tested for non-inferiority.</p><p><strong>Type 1 Diabetes &ndash; Pediatrics </strong></p><p>PRONTO-Peds (NCT03740919) was a 26-week, randomized (2:2:1), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 716 patients with type 1 diabetes. Patients were randomized to either blinded mealtime LYUMJEV (N=280), blinded mealtime HUMALOG (N=298), or open-label postmeal LYUMJEV (N=138), all in combination with basal insulin (insulin glargine, insulin degludec or insulin detemir). Mealtime LYUMJEV or HUMALOG was injected 0 to 2 minutes before the meal and postmeal LYUMJEV was injected within 20 minutes after the start of the meal.</p><p>Patients had a mean age of 12 years; mean duration of diabetes of 5 years; 51% were male; race: 89% White, 6% Asian, and 2% Black or African American. Twenty-four percent of the randomized patients were Hispanic. The mean BMI was 20.4 kg/m2.</p><p>At week 26, treatment with mealtime LYUMJEV provided a mean reduction in HbA1c that met the pre-specified non-inferiority margin (0.4%) (see Table 9). In addition, postmeal LYUMJEV met the prespecified non-inferiority margin (0.4%) compared to mealtime HUMALOG. Insulin doses were similar in all treatment groups at baseline and at 26 weeks.</p><p>&nbsp;</p><p><strong>Table 9. Results from Study PRONTO-Peds: 26 Week Trial of Mealtime LYUMJEV and Postmeal LYUMJEV compared with Mealtime HUMALOG, all in Combination with Basal Insulin in Pediatrics with Type 1 Diabetes</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mealtime LYUMJEV + basal insulin </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mealtime HUMALOG + basal insulin </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Postmeal LYUMJEV + basal insulin </strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Number of randomized subjects (N) </strong></p></td><td style="vertical-align:top"><p>280</p></td><td style="vertical-align:top"><p>298</p></td><td style="vertical-align:top"><p>138</p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA</strong><strong>1c </strong><strong>(%) (mean)</strong><strong>a,b </strong></p><p>Baseline</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>7.8</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted mean change from baseline</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td><td style="vertical-align:top"><p>0.06</p></td></tr><tr><td style="vertical-align:top"><p>Estimated treatment difference versus HUMALOG [95% CI]c</p></td><td style="vertical-align:top"><p>-0.01 [-0.15, 0.14]</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>-0.00 [-0.18, 0.18]</p><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 26 were imputed by return to baseline approach. At week 26, primary efficacy assessment was missing for 5.4%, 7.1%, and 5.1% of subjects, for mealtime LYUMJEV, mealtime HUMALOG, and postmeal LYUMJEV, respectively.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup> Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.</p><p><sup>c</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tested for non-inferiority.</p><p>Type 2 Diabetes &ndash; Adults</p><p>PRONTO-T2D (NCT03214380) was a 26-week, randomized (1:1), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 673&nbsp;patients with type 2 diabetes who at study entry were on up to three oral anti-diabetic medications (OAMs), basal insulin and at least one prandial insulin injection or premixed insulin with at least two injections daily. Patients were allowed to continue on metformin and/or a SGLT2 inhibitor and were randomized to either mealtime LYUMJEV (N=336) or to mealtime HUMALOG (N=337), both in combination with insulin glargine or insulin degludec in a basal-bolus regimen. Mealtime LYUMJEV or mealtime HUMALOG was injected 0-2&nbsp;minutes before the meal.</p><p>Patients had a mean age of 61 years; mean duration of diabetes of 17 years; 53% were male; race: 69% White, 24% Asian, and 5% Black or African American. Twenty-three percent of the randomized patients were Hispanic. The mean BMI was 32.3&nbsp;kg/m<sup>2</sup>.</p><p>At week 26, treatment with mealtime LYUMJEV provided a mean reduction of HbA<sub>1c</sub> from baseline that met the pre-specified non-inferiority margin (0.4%) compared to mealtime HUMALOG (see Table 10). Insulin doses were similar in both treatment groups at baseline and at 26&nbsp;weeks.</p><p>&nbsp;</p><p>Table 10. Results from Study PRONTO-T2D: 26 Week Trial of Mealtime LYUMJEV Compared with Mealtime HUMALOG, both in Combination with Basal Insulin in Adults with Type 2 Diabetes</p><table border="1" cellspacing="0" cellpadding="0" style="width:720px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mealtime LYUMJEV + basal insulin</p></td><td style="vertical-align:top"><p>Mealtime HUMALOG + basal insulin</p></td></tr><tr><td style="vertical-align:top"><p>Number of randomized subjects (N)</p></td><td style="vertical-align:top"><p>336</p></td><td style="vertical-align:top"><p>337</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>HbA<sub>1c</sub> (%)<sup>a,b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Baseline mean</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>7.3</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Adjusted mean change from baseline</p></td><td style="vertical-align:top"><p>-0.36</p></td><td style="vertical-align:top"><p>-0.38</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Estimated treatment difference versus HUMALOG [95% CI]<sup>c</sup></p></td><td style="vertical-align:top"><p>0.03 [-0.08, 0.13]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 26 were imputed by return to baseline approach. At week 26, primary efficacy assessment was missing for 4.8% of subjects for mealtime LYUMJEV and for 4.5% mealtime HUMALOG.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; Tested for non-inferiority.</p><p>Type 1 Diabetes &ndash; Adults Continuous Subcutaneous Insulin Infusion (CSII)</p><p>PRONTO-Pump-2 (NCT03830281) was a 16 week randomized (1:1), active controlled, treat-to-target, multinational trial that evaluated the efficacy of LYUMJEV in 432 patients with type 1 diabetes currently using continuous subcutaneous insulin infusion. Patients were randomized to either blinded LYUMJEV (N=215) or blinded HUMALOG (N= 217). Mealtime LYUMJEV or HUMALOG boluses were initiated 0 to 2 minutes before the meal.</p><p>Patients had a mean age of 46 years; mean duration of diabetes of 26 years; 45% were male; race: 95% White, 3% Black or African American, and 0.5% Asian. Eight percent of the randomized patients were Hispanic. The mean BMI was 27.1&nbsp;kg/m<sup>2</sup>.</p><p>At week 16, treatment with LYUMJEV provided a mean reduction in HbA<sub>1c</sub> that met the pre-specified non-inferiority margin (0.4%) compared to mealtime HUMALOG (see Table 11). Total daily insulin doses were similar for both treatment groups at baseline and at 16 weeks.</p><p>&nbsp;</p><p>Table 11. Results from Study PRONTO-Pump-2: 16 Week Trial of LYUMJEV compared with HUMALOG in Adults with Type 1 Diabetes</p><table border="1" cellspacing="0" cellpadding="0" style="width:720px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>LYUMJEV</p></td><td style="vertical-align:top"><p>HUMALOG</p></td></tr><tr><td style="vertical-align:top"><p>Number of randomized subjects (N)</p></td><td style="vertical-align:top"><p>215</p></td><td style="vertical-align:top"><p>217</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>HbA<sub>1c</sub> (%)<sup>a,b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Baseline mean</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>7.5</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Adjusted mean change from baseline</p></td><td style="vertical-align:top"><p>-0.06</p></td><td style="vertical-align:top"><p>-0.09</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Estimated treatment difference versus HUMALOG [95% CI]<sup>c</sup></p></td><td style="vertical-align:top"><p>0.03 [-0.05, 0.11]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Analysis population: all randomized subjects regardless of adherence to treatment or availability of post-baseline assessment. Missing data at Week 16 were imputed by return to baseline approach. At week 16, primary efficacy assessment was missing for 7% and 4.6% of subjects, for LYUMJEV and HUMALOG, respectively.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Least-squares (LS) mean from ANCOVA adjusted for baseline value and other stratification factors.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Tested for non-inferiority.</p><p><strong>&nbsp;</strong></p><p><strong>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p><strong>&nbsp;</strong></p><p>Absorption</p><p>Absorption of insulin lispro was evaluated in healthy subjects (see Figure 2) and patients with diabetes following subcutaneous injection of LYUMJEV.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Insulin lispro appeared in circulation approximately 1&nbsp;minute after injection of LYUMJEV.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Time to 50% maximum insulin lispro concentration was 13&nbsp;minutes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Time to maximum insulin lispro concentration was achieved at 57&nbsp;minutes.</p><p>In healthy subjects, the day-to-day variability [CV%] within subjects of LYUMJEV was 10% for total exposure (AUC, 0‑10h) and 16% for maximum insulin lispro concentration (Cmax).</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:323pt;height:286pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/L003363/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="ITSH_Lyumjev_Label_Plot_15May2020"/>
</v:shape><![endif]--><img width="431" height="381" src="file:///C:/Users/L003363/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>Figure 2. Mean Serum Insulin Lispro After Subcutaneous Injection of LYUMJEV (15 unit dose) in Healthy Subjects</p><p>&nbsp;</p><p>The absolute bioavailability of insulin lispro after subcutaneous administration of LYUMJEV in the abdomen, deltoid, and thigh was approximately 65%. The rate of absorption of insulin lispro is maintained regardless of injection site. Maximum concentration and time to maximum concentration were comparable for the abdomen and upper arm regions; time to maximum concentration was longer and maximum concentration was lower for the thigh.</p><p>Total insulin lispro exposure and maximum insulin lispro concentration increased proportionally with increasing subcutaneous doses of LYUMJEV within the therapeutic dose range.</p><p>The results of a study in healthy subjects demonstrated that LYUMJEV 200 units/mL is bioequivalent to LYUMJEV 100&nbsp;units/mL following administration of a single 15&nbsp;unit dose for the area under the serum insulin lispro concentration-time curve from time zero to infinity and maximum insulin lispro concentration. The rate of insulin lispro absorption after administration of LYUMJEV 200&nbsp;units/mL was similar as observed with LYUMJEV 100&nbsp;units/mL.</p><p>Distribution</p><p>Following a 15&nbsp;unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) volume of distribution of insulin lispro (Vd) was 34&nbsp;L&nbsp;(30%).</p><p>Elimination</p><p>Following a 15&nbsp;unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) clearance of insulin lispro was 32&nbsp;L/hour&nbsp;(22%) and the median half-life of insulin lispro was 44&nbsp;minutes.</p><p>Specific Populations</p><p>Age, gender, and race did not affect the pharmacokinetics and pharmacodynamics of LYUMJEV.</p><p>Patients with Renal and Hepatic Impairment</p><p>Renal and hepatic impairment is not known to impact the pharmacokinetics of insulin lispro. Insulin requirements may be reduced in the presence of renal or hepatic impairment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Absorption</p><p>Absorption of insulin lispro was evaluated in healthy subjects (see Figure 2) and patients with diabetes following subcutaneous injection of LYUMJEV.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Insulin lispro appeared in circulation approximately 1&nbsp;minute after injection of LYUMJEV.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Time to 50% maximum insulin lispro concentration was 13&nbsp;minutes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Time to maximum insulin lispro concentration was achieved at 57&nbsp;minutes.</p><p>In healthy subjects, the day-to-day variability [CV%] within subjects of LYUMJEV was 10% for total exposure (AUC, 0‑10h) and 16% for maximum insulin lispro concentration (Cmax).</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:323pt;height:286pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/c259540/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="ITSH_Lyumjev_Label_Plot_15May2020"/>
</v:shape><![endif]--><img width="431" height="381" src="file:///C:/Users/c259540/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>Figure 2. Mean Serum Insulin Lispro After Subcutaneous Injection of LYUMJEV (15 unit dose) in Healthy Subjects</p><p>&nbsp;</p><p>The absolute bioavailability of insulin lispro after subcutaneous administration of LYUMJEV in the abdomen, deltoid, and thigh was approximately 65%. The rate of absorption of insulin lispro is maintained regardless of injection site. Maximum concentration and time to maximum concentration were comparable for the abdomen and upper arm regions; time to maximum concentration was longer and maximum concentration was lower for the thigh.</p><p>Total insulin lispro exposure and maximum insulin lispro concentration increased proportionally with increasing subcutaneous doses of LYUMJEV within the therapeutic dose range.</p><p>The results of a study in healthy subjects demonstrated that LYUMJEV 200 units/mL is bioequivalent to LYUMJEV 100&nbsp;units/mL following administration of a single 15&nbsp;unit dose for the area under the serum insulin lispro concentration-time curve from time zero to infinity and maximum insulin lispro concentration. The rate of insulin lispro absorption after administration of LYUMJEV 200&nbsp;units/mL was similar as observed with LYUMJEV 100&nbsp;units/mL.</p><p>Distribution</p><p>Following a 15&nbsp;unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) volume of distribution of insulin lispro (Vd) was 34&nbsp;L&nbsp;(30%).</p><p>Elimination</p><p>Following a 15&nbsp;unit intravenous bolus injection of LYUMJEV in healthy subjects, the geometric mean (CV%) clearance of insulin lispro was 32&nbsp;L/hour&nbsp;(22%) and the median half-life of insulin lispro was 44&nbsp;minutes.</p><p>Specific Populations</p><p>Age, gender, and race did not affect the pharmacokinetics and pharmacodynamics of LYUMJEV.</p><p>Patients with Renal and Hepatic Impairment</p><p>Renal and hepatic impairment is not known to impact the pharmacokinetics of insulin lispro. Insulin requirements may be reduced in the presence of renal or hepatic impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NONCLINICAL TOXICOLOGY</p><p>Carcinogenesis, Mutagenesis, Impairment of Fertility</p><p>In Fischer 344 rats, a 12-month repeat-dose toxicity study was conducted with insulin lispro at subcutaneaaaous doses of 20 and 200&nbsp;units/kg/day (approximately 3 and 32&nbsp;times the human subcutaneous dose of 1&nbsp;unit/kg/day, based on units/body surface area). Insulin lispro did not produce important target organ toxicity including mammary tumors at any dose.</p><p>Insulin lispro was not mutagenic in the following genetic toxicity assays: bacterial mutation, unscheduled DNA synthesis, mouse lymphoma, chromosomal aberration, and micronucleus assays.</p><p>Male fertility was not compromised when male rats given subcutaneous insulin lispro injections of 5 and 20&nbsp;units/kg/day (0.8 and 3&nbsp;times the human subcutaneous dose of 1&nbsp;unit/kg/day, based on units/body surface area) for 6&nbsp;months were mated with untreated female rats. In a combined fertility, perinatal, and postnatal study in male and female rats given 1, 5, and 20&nbsp;units/kg/day subcutaneously (0.2, 0.8, and 3&nbsp;times the human subcutaneous dose of 1&nbsp;unit/kg/day, based on units/body surface area), mating and fertility were not adversely affected in either gender at any dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>glycerol (12.1&nbsp;mg),</p><p>magnesium chloride hexahydrate (1.02&nbsp;mg),</p><p>metacresol (3.15&nbsp;mg),</p><p>sodium citrate dihydrate (4.41&nbsp;mg),</p><p>treprostinil sodium (1.06&nbsp;mcg),</p><p>zinc oxide (content adjusted to provide 39 mcg of zinc ion for 100units/mL and 52&nbsp;mcg for 200units/ml),</p><p>and Water for Injection, USP.</p><p>Hydrochloric acid and/or sodium hydroxide may be added to adjust the pH. LYUMJEV has a pH of 7.0 to 7.8.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Dispense in the original sealed carton with the enclosed Instructions for Use.</p><p><strong>Cartridges and Pens Special Precautions for Storage</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protect from direct heat and light [or sunlight]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DO NOT FREEZE</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store not in-use (unopened) cartridges and pens in a refrigerator at 2&deg;C to 8&deg;C [36&deg;F to 46&deg;F] until time of use</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store in-use cartridges and pens (after the disc seal has been punctured) in a refrigerator</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in-use cartridges and pens for up to 28 days at a maximum temperature of 30˚C [86˚F]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lilly 3 mL cartridges: Designed and tested for use only with Lilly pens</p><p>&nbsp;</p><p><strong>10 mL Vial (100 units/mL Only) Special Precautions for Storage </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protect from direct heat and light [or sunlight]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DO NOT FREEZE</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store drug product in a refrigerator at 2&deg;C to 8&deg;C [36&deg;F to 46&deg;F] until time of use.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in-use vials (after the stopper has been punctured) refrigerated for up to 28 days. If refrigeration is not possible, an in-use vial can be kept unrefrigerated for up to 28 days at a maximum temperature of 30&deg;C [86&deg;F]. In-use vials can only be used for a total of 28 days, including both refrigerated and unrefrigerated storage time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [Drug product in a pump can be used for a maximum of 9 days. Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.]</p><p>&nbsp;</p><p><strong>Handling of Prepared Dosing Solution &ndash; IV Use</strong></p><p>Stable up to 14 days when diluted to concentrations of 0.1 to 1 U/mL in 5% Dextrose Injection or 0.9% Sodium Chloride Injection when stored in a refrigerator at 2&deg;C to 8&deg;C [36&deg;F to 46&deg;F] until time of use. The same solutions may be stored for up to 20 hours at room temperature at 20&deg;C to 25&deg;C [(68&deg;F to 77&deg;F)].</p><p>&nbsp;</p><p>The storage conditions for vials, pens, and cartridges are summarized in Table 12.</p><p>Table 12. Storage Conditions for Vials, Pens, and Cartridges</p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td style="vertical-align:top"><p><strong>LYUMJEV Presentation</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Not In-use</strong></p><p><strong>(Unopened)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>In-use</strong></p><p><strong>(Opened)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Room Temperature (below 86&deg;F [30&deg;C])</strong></p><p><strong>&nbsp;</strong></p></td><td><p><strong>Refrigerated</strong></p><p><strong>(36&deg;F to 46&deg;F </strong></p><p><strong>[2&deg;C to 8&deg;C])</strong></p></td><td style="vertical-align:top"><p><strong>Room Temperature (below 86&deg;F [30&deg;C])</strong></p></td><td><p><strong>Refrigerated</strong></p><p><strong>(36&deg;F to 46&deg;F [2&deg;C to 8&deg;C])</strong></p></td></tr><tr><td style="vertical-align:top"><p>10&nbsp;mL vial<sup>a,b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;mL cartridge<sup>b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Do not refrigerate</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;mL LYUMJEV KwikPen (U‑100 and U‑200)<sup>b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Do not refrigerate</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;mL LYUMJEV Junior KwikPen<sup>b</sup></p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Until expiration date</p></td><td style="vertical-align:top"><p>28 days</p></td><td style="vertical-align:top"><p>Do not refrigerate</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; In-use (opened) vials, whether or not refrigerated, must be used within 28&nbsp;days.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; When stored at room temperature, LYUMJEV can only be used for a total of 28&nbsp;days including both not in-use (unopened) and in-use (opened) storage time.</p><p>Storage of LYUMJEV in Insulin Pump</p><p>Change the LYUMJEV U-100 in the pump reservoir at least every 9 days, or according to the pump user manual, whichever is shorter, or after exposure to temperatures that exceed 37&deg;C (98.6&deg;F).</p><p>Storage of LYUMJEV in Intravenous Infusion Fluids</p><p>Diluted LYUMJEV may be stored for up to 4 days when refrigerated at 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C) until time of use. The same solution may be stored up to 12&nbsp;hours at room temperature at 68&deg;F to 77&deg;F (20&deg;C to 25&deg;C) <em>[see Dosage and Administration (4.2)].</em></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LYUMJEV (insulin lispro) injection is a clear and colorless solution available as shown in Table 13.</p><p>&nbsp;</p><p>Table 13. How Supplied</p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>LYUMJEV</p></td><td style="vertical-align:top"><p>Concentration</p></td><td style="vertical-align:top"><p>Total Units in Presentation</p></td><td style="vertical-align:top"><p>Dose Increment</p></td><td style="vertical-align:top"><p>Package Size</p></td></tr><tr><td style="vertical-align:top"><p>U-100 multiple-dose 10&nbsp;mL vial</p></td><td style="vertical-align:top"><p>100&nbsp;units/mL</p></td><td style="vertical-align:top"><p>1,000&nbsp;units</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>1&nbsp;vial</p></td></tr><tr><td style="vertical-align:top"><p>U-100 single-patient-use 3&nbsp;mL cartridge<sup>a </sup></p></td><td style="vertical-align:top"><p>100&nbsp;units/mL</p></td><td style="vertical-align:top"><p>300&nbsp;units</p></td><td style="vertical-align:top"><p>n/a</p></td><td style="vertical-align:top"><p>5&nbsp;cartridges</p></td></tr><tr><td style="vertical-align:top"><p>U-100 single-patient-use 3&nbsp;mL KwikPen</p></td><td style="vertical-align:top"><p>100&nbsp;units/mL</p></td><td style="vertical-align:top"><p>300&nbsp;units</p></td><td style="vertical-align:top"><p>1&nbsp;unit</p></td><td style="vertical-align:top"><p>5&nbsp;pens</p></td></tr><tr><td style="vertical-align:top"><p>U-100 single-patient-use 3&nbsp;mL Junior KwikPen</p></td><td style="vertical-align:top"><p>100&nbsp;units/mL</p></td><td style="vertical-align:top"><p>300&nbsp;units</p></td><td style="vertical-align:top"><p>0.5&nbsp;unit</p></td><td style="vertical-align:top"><p>5&nbsp;pens</p></td></tr><tr><td style="vertical-align:top"><p>U-200 single-patient-use 3&nbsp;mL KwikPen</p></td><td style="vertical-align:top"><p>200&nbsp;units/mL</p></td><td style="vertical-align:top"><p>600&nbsp;units</p></td><td style="vertical-align:top"><p>1&nbsp;unit</p></td><td style="vertical-align:top"><p>5&nbsp;pens</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp; 3&nbsp;mL cartridge is for use in Eli Lilly and Company&#39;s insulin delivery device. Patients need to check their device manual to determine if the LYUMJEV cartridge is compatible for use in other devices.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>PATIENT COUNSELING INFORMATION</p><p>Advise the patient to read the FDA-Approved Patient Labeling (Patient Information and Instructions for Use).</p><p>Never Share a LYUMJEV Prefilled Pen, Cartridge, or Syringe Between Patients</p><p>Advise patients that they must never share a LYUMJEV prefilled pen or cartridge with another person, even if the needle is changed. Advise patients using LYUMJEV vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens <em>[see Warnings and Precautions (5.1)]</em>.</p><p>Hyperglycemia or Hypoglycemia</p><p>Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of LYUMJEV therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia.</p><p>Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery <em>[see Warnings and Precautions (5.3)]</em>.</p><p>Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision <em>[see Warnings and Precautions (5.2)].</em></p><p>Hypoglycemia due to Medication Errors</p><p>Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products.<em> </em></p><p>Inform patients that LYUMJEV U-200 contains 2 times as much insulin per mL as LYUMJEV U-100. The LYUMJEV U-200 KwikPen dose window shows the number of units of LYUMJEV U-200 to be injected so no dose conversion is required <em>[see Dosage and Administration (2.1)].</em></p><p>Instruct patients to not transfer LYUMJEV U-200 from the LYUMJEV U-200 KwikPen to a syringe <em>[see Warnings and Precautions (5.4)].</em></p><p>Hypersensitivity Reactions</p><p>Advise patients that hypersensitivity reactions have occurred with LYUMJEV. Inform patients on the symptoms of hypersensitivity reactions <em>[see Warnings and Precautions (5.6)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly and Company, Indianapolis, IN 46285, USA

MARKETING AUTHORISATION NUMBER(S) 

LYUMJEV 100 units/mL 3 mL single-patient-use KwikPen: 2002221736
LYUMJEV 200 units/mL 3 mL single-patient-use KwikPen: 2002221734
LYUMJEV 100 units/mL 10 mL multiple-dose vial: 2002221735
LYUMJEV 100 units/mL 3 mL single-patient-use Junior KwikPen: 2002221733

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorization: 20 February 2022


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                13  August 2021
Version 3

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>